Kevin Rakin

Kevin is co-founder of HighCape Capital, a growth equity firm that finances and assists innovative life sciences companies transition from the initial stages of their business cycle into successful, thriving organizations. He was also CEO of HighCape Capital Acquisition Corporation, a SPAC that completed a merger with Quantum-Si in June 2021.

Kevin has more than 30 years of experience as an investor and executive in the life sciences industry.  Prior to founding HighCape in 2013 he served as president of Shire Regenerative Medicine and prior to that role was chairman and chief executive officer of Advanced BioHealing from 2007 until its acquisition by Shire in 2011 for $750 million. Before that, he served as an executive-in-residence at Canaan Partners. Previously, he was a co-founder, president and chief executive officer of Genaissance Pharmaceuticals, a publicly traded pharmacogenomics company, until its merger with Clinical Data in 2005.

His board memberships include Elutia (chairman), Wellinks (chairman), Cybrexa, Nyxoah SA, Quantum-Si, Alphina Therapeutics and CapeHaven.

He has previously served as a board member for Modifi Biosciences, Cheetah Medical, Collagen Matrix,  TELA Bio, Histogenics Corporation, Oramed Pharmaceuticals, Ipsogen SA, VionPharmaceuticals, OMRIX Biopharmaceutical and Clinical Data.

Kevin received an MBA from Columbia University and B.Com and B.Com (Hons) from the University of Cape Town, South Africa.